The acid-sensitive APIs market is projected to grow from USD 15.64 billion in 2025 to USD 23.83 billion by 2035, registering a CAGR of 4.3%. Omeprazole/Esomeprazole will lead the molecule segment with a 22% share, while proton pump inhibitors will dominate the therapeutic class, accounting for 32.6% in 2025.